Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study. - Centre de recherche Saint-Antoine - UMR S938 Access content directly
Journal Articles Journal of Clinical Medicine Year : 2022

Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study.

A. Waszczuk-Gajda
  • Function : Author
O. Penack
  • Function : Author
G. Sbianchi
  • Function : Author
L. Koster
  • Function : Author
P. Reményi
  • Function : Author
N. Russell
  • Function : Author
P. Ljungman
  • Function : Author
M. Trneny
  • Function : Author
J. Mayer
  • Function : Author
S. Iacobelli
  • Function : Author
G. Kobbe
  • Function : Author
C. Scheid
  • Function : Author
J. Apperley
  • Function : Author
S. Lenhoff
  • Function : Author
E. Jantunen
  • Function : Author
A. Anagnostopoulos
  • Function : Author
L. Paris
  • Function : Author
P. Browne
  • Function : Author
N. Schaap
  • Function : Author
J. Sierra
  • Function : Author
J. Styczynski
  • Function : Author
H. Schoemans
  • Function : Author
I. Moiseev
  • Function : Author
R. F. Duarte
  • Function : Author
Z. Peric
  • Function : Author
S. Montoto
  • Function : Author
A. van Biezen
  • Function : Author
M. Mikulska
  • Function : Author
M. Aljurf
  • Function : Author
T. Ruutu
  • Function : Author
N. Kröger
  • Function : Author
C. Morris
  • Function : Author
C. Koenecke
  • Function : Author
S. Schoenland
  • Function : Author
G. W. Basak
  • Function : Author

Abstract

Background: The main goal of this post hoc analysis of the Collaboration to Collect Autologous Transplant Outcomes in Lymphoma and Myeloma (CALM) study was to evaluate the rate of short- and long-term infectious and non-infectious complications occurring after ASCT in patients with multiple myeloma (MM). Methods: The analysis included all patients with MM from the CALM study who underwent ≥1 ASCT. The primary endpoint of the analysis was to determine the rate of infectious and non-infectious complications after ASCT and to compare them in three time periods: 0–100 days, 101 days–1 year, and >1 year after the first transplant. Results: The analysis included a total of 3552 patients followed up for a median of 56.7 months (range 0.4–108.1). Complication rates decreased with the time from ASCT with 24.85 cases per 100 patient-years from day 0 to 100 days after the transplant, and <2.31 cases per 100 patient-years from the 101st day. At 100 days after ASC T, 45.7% of patients had complications, with infectious events being twice as frequent as non-infectious complications. Bacterial infections (6.5 cases per 100 patient-years, 95% CI: 6.1–7.0) and gastrointestinal complications (4.7 cases per 100 patient-years, 95% CI: 4.3–5.1) were the most common early events. The pattern of complications changed with time from ASCT. The presence of complications after ASCT was not associated with overall survival. Conclusions: Our data provide a solid basis for comparing ASCT-related complications to those caused by emerging treatments in multiple myeloma, such as CAR T-cell therapy and other immunotherapies.
Fichier principal
Vignette du fichier
jcm-11-03541-v2.pdf (1.02 Mo) Télécharger le fichier
Origin : Publisher files allowed on an open archive

Dates and versions

hal-04523072 , version 1 (27-03-2024)

Licence

Attribution

Identifiers

Cite

A. Waszczuk-Gajda, O. Penack, G. Sbianchi, L. Koster, Didier Blaise, et al.. Complications of Autologous Stem Cell Transplantation in Multiple Myeloma: Results from the CALM Study.. Journal of Clinical Medicine, 2022, Journal of Clinical Medicine, 11, pp.35-41. ⟨10.3390/jcm11123541⟩. ⟨hal-04523072⟩
7 View
1 Download

Altmetric

Share

Gmail Facebook X LinkedIn More